Innate Pharma
IPHA
9 hedge funds and large institutions have $235K invested in Innate Pharma in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0.1% less ownership
Funds ownership: 0.3% → 0.2% (-0.1%)
18% less funds holding
Funds holding: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
51% less capital invested
Capital invested by funds: $483K → $235K (-$248K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$80.6K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$49.8K |
| 3 |
Millennium Management
New York
|
-$16.7K |
| 4 |
Morgan Stanley
New York
|
-$4.69K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
-$1.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPC
1
Lion Point Capital
New York
| $104K | – | – | – |
|
|
2
Morgan Stanley
New York
| $55.7K | -$4.69K | -2,870 | -6% |
|
|
3
Jane Street
New York
| $55.5K | -$80.6K | -49,388 | -53% |
|
|
4
Millennium Management
New York
| $12.9K | -$16.7K | -10,244 | -50% |
|
5
RhumbLine Advisers
Boston,
Massachusetts
| $6.06K | -$767 | -470 | -9% |
|
6
UBS Group
Zurich,
Switzerland
| $1.1K | -$140 | -86 | -9% |
|
|
GI
7
GAMMA Investing
Foster City,
California
| $307 | -$1.36K | -833 | -78% |
|
|
FFA
8
Farther Finance Advisors
San Francisco,
California
| $14 | – | – | – |
|
|
CIAM
9
Caitong International Asset Management
Hong Kong
| $3 | +$3 | +2 | New |
|
|
OMC
10
Old Mission Capital
Chicago,
Illinois
| – | -$49.8K | -28,431 | Closed |
|
11
Barclays
London,
United Kingdom
| – | -$2 | -1 | Closed |
|
IPHA Hedge Fund Activity: Q1 2026 in Review
9 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2026, worth a combined $235K — down 51% from $483K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 0 added.
The largest buyer was Caitong International Asset Management, opening a new position worth an estimated $3. The largest seller was Jane Street, cutting an estimated $80.6K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q1 2026, down from 11 in Q4 2025.
- Funds reported $235K of Innate Pharma stock for Q1 2026, down 51% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q1 2026 was Caitong International Asset Management, an estimated $3 added.
- The largest Innate Pharma seller in Q1 2026 was Jane Street, an estimated $80.6K sold.
Based on aggregated 13F filings for Q1 2026.